Anti-CD20 antibody induces the improvement of cytokine-induced killer cell activity via the STAT and MAPK/ERK signaling pathways

Experimental and Therapeutic Medicine

Volumn 9, Issue 4, 2015, Pages 1215-1222

  Deng, Qi ^a   Bai, Xue ^a   Lv, Hai Rong ^a   Xiao, Xia ^a   Zhao, Ming Feng ^a   Li, Yu Ming ^a  

^a TIANJIN FIRST CENTRAL HOSPITAL   (China)

Author keywords

Cell therapy; Cytokine induced killer; Human B cell lymphoma cell lines; K562; Rituximab; Signaling pathway

Indexed keywords

FAS LIGAND; GAMMA INTERFERON; GRANZYME B; LYMPHOTOXIN; MITOGEN ACTIVATED PROTEIN KINASE; PERFORIN; RITUXIMAB; STAT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER CELL LINE; CELL CULTURE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; CYTOTOXICITY ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84922981775     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2264     Document Type: Article

References (24)

1. Dölken G: Detection of minimal residual disease. Adv Cancer Res 82: 133-185, 2001.
2. Scheffold C, Brandt K, Johnston V, et al: Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplant 15: 33-39, 1995.
3. Nagaraj S, Ziske C and Schmidt Wolf IG: Human cytokine induced killer cells have enhanced in vitro cytolytic activity via non viral interleukin 2 gene transfer. Genet Vaccines Ther 2: 12, 2004.
4. Edinger M, Cao YA, Verneris MR, et al: Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 101: 640-648, 2003.
5. Marin V, Dander E, Biagi E, et al: Characterization of in vitro migratory properties of anti CD19 chimeric receptor redirected CIK cells for their potential use in B ALL immunotherapy. Exp Hematol 34: 1219-1229, 2006.
6. Shi M, Zhang B, Tang ZR, et al: Autologous cytokine induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 10: 1146-1151, 2004.
7. Introna M, Borleri G, Conti E, et al: Repeated infusions of donor derived cytokine induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 92: 952-959, 2007.
8. Feugier P, Van Hoof A, Sebban C, et al: Long term results of the R CHOP study in the treatment of elderly patients with diffuse large B cell lymphoma: a study by the Groupe d'Etude des Lymphomes de I'Adulte. J Clin Oncol 23: 4117-4126, 2005.
9. Habermann TM, Weller EA, Morrison VA, et al: Rituximab CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B cell lymphoma. J Clin Oncol 24: 3121-3127, 2006.
10. Pfreundschuh M, Trümper L, Osterborg A, et al; MabThera International Trial Group: CHOP like chemotherapy plus rituximab versus CHOP like chemotherapy alone in young patients with good prognosis diffuse large B cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7: 379-391, 2006.
11. Leemhuis T, Wells S, Scheffold C, et al: A phase I trial of autologous cytokine induced killer cells for the treatment of relapsed Hodgkin disease and non Hodgkin lymphoma. Biol Blood Marrow Transplant 11: 181-187, 2005.
12. Linn YC and Hui KM: Cytokine induced killer cells: NK like T cells with cytotolytic specificity against leukemia. Leuk Lymphoma 44: 1457-1462, 2003.
13. Verneris MR, Ito M, Baker J, et al: Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 7: 532-542, 2001.
14. Verneris MR, Karami M, Baker J, et al: Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103: 3065-3072, 2004.
15. Alvarnas JC, Linn YC, Hope EG and Negrin RS: Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 7: 216-222, 2001.
16. Pievani A, Belussi C, Klein C, et al: Enhanced killing of human B cell lymphoma targets by combined use of cytokine induced killer cell (CIK) cultures and anti CD20 antibodies. Blood 117: 510-518, 2011.
17. David M: Signal transduction by type I interferons. Biotechniques Suppl: 58-65, 2002.
18. Moro H, Otero DC, Tanabe Y and David M: T cell intrinsic and extrinsic contributions of the IFNAR/STAT1 axis to thymocyte survival. PLoS One 6: e24972, 2011.
19. Zeng R, Spolski R, Casas E, et al: The molecular basis of IL 21 mediated proliferation. Blood 109: 4135-4142, 2007.
20. Eckelhart E, Warsch W, Zebedin E, et al: A novel Ncr1 Cre mouse reveals the essential role of STAT5 for NK cell survival and development. Blood 117: 1565-1573, 2011.
21. Hand TW, Cui W, Jung YW, et al: Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T cell survival. Proc Natl Acad Sci USA 107: 16601-16606, 2010.
22. Santen RJ, Song RX, McPherson R, et al: The role of mitogen activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80: 239-256, 2002.
23. Frigo DE, Tang Y, Beckman BS, et al: Mechanism of AP 1 mediated gene expression by select organochlorines through the p38 MAPK pathway. Carcinogenesis 25: 249-261, 2004.
24. Antoon JW, Nitzchke AM, Martin EC, et al: Inhibition of p38 mitogen activated protein kinase alters microRNA expression and reverses epithelial to mesenchymal transition. Int J Oncol 42: 1139-1150, 2013.